Anthropic buys Coefficient Bio for $400M

Anthropic acquired Coefficient Bio for about $400 million in stock, folding the stealth biotech startup into its health and life-sciences effort. (pharmavoice.com) (techcrunch.com) Coefficient Bio was only about eight months old and had fewer than 10 employees when the deal closed in early April 2026, according to reports. (pharmavoice.com) (techcrunch.com) The startup was founded by Nathan C. Frey and Samuel Stanton, two former Genentech researchers who worked in computational drug discovery at Prescient Design. (techcrunch.com) (pharmaphorum.com) Coefficient Bio had been building artificial intelligence tools for drug discovery and scientific experimentation, a field that uses software to help researchers pick targets, design molecules, and test ideas faster. (techcrunch.com) (economictimes.indiatimes.com) Anthropic had already been moving into that market. In October 2025, it launched Claude for Life Sciences, and in January 2026 it expanded into healthcare with HIPAA-ready products and connectors to systems including Medidata, the Centers for Medicare and Medicaid Services, and ClinicalTrials.gov. (rdworldonline.com) (anthropic.com) Anthropic also said companies including Novo Nordisk, Sanofi, AbbVie, and Genmab were already using Claude in life sciences and healthcare workflows. (anthropic.com) (fiercehealthcare.com) PharmaVoice reported that Nathan Frey is now Anthropic’s life sciences lead, while Samuel Stanton is on Anthropic’s technical staff, showing the acquisition was as much about talent as software. (pharmavoice.com) The price tag worked out to roughly $40 million per employee if the team size was under 10, an unusually high ratio for a startup that had operated mostly in stealth. (pharmavoice.com) (thenextweb.com) The acquisition leaves Anthropic with a deeper bench in biology just months after it started selling specialized tools to drugmakers, hospitals, and health insurers. (anthropic.com) (pharmavoice.com)